



## Nebraska Medicaid DUR Board Meeting Tuesday May 13th, 2025

**DUR Board Members in attendance:** Marin Broucek, M.D., Matt Titchener R.P., Charlie Moore, R.P., Jaci Timmons, M.D. Absent: David Randolph, R.P.

**Nebraska Medicaid & LTC attendees in attendance:** Lee Stutzman, R.P., Pharmacy Director; Leah Spencer, R.N. Program Specialist, Dianne Garside, R.P., Spencer Moore, R. P.

**Contracted attendees:** Jamie Benson, R.P., Nebraska Total Care; Shannon Nelson, R.P., Molina Healthcare of Nebraska; Bernadette Ueda, R.P., United Healthcare; Shaleigh Hammons, Account Executive, Prime Therapeutics, Nikia Bennette-Carter, R.P. Pharmacist Prime Therapeutics

**Public Attendees in attendance:** Jessi Bennett, Biocryst; Jodi Fuehrer, APRN; Kurt Hendrickson, AbbVie; Amy Hornig, AbbVie; Jeff Houston, AbbVie; Amanda Nowakowski, ViiV Healthcare; Randall Roth, Merck; Tami Sova, Biogen; Justin Springfield, Gilead.

### I. Opening and Introductions

Lee Stutzman called the meeting to order at 6:30pm. The meeting was held at the Best Western Plus Lincoln Inn & Suites in Lincoln, NE. A copy of the open meetings act was available. Dr Jaci Timmons was introduced as the newest DUR Board member.

II. Declaration of any Conflict of Interest or changes  
No Changes in conflict of interest were declared.

III. Agenda approval  
The agenda was unanimously approved.

IV. Review and Approval of Minutes from previous Board meeting January 14, 2025  
The vote was as follows:-Broucek, yes; Moore, yes; Timmons, abstain; Titchener, yes.

V. Update on Recommendations from Previous Meeting  
Stutzman announced the State will re-visit the previously discussed topics of high-cost medications, substance use disorder and benzodiazepines, and GLP-1 with DPP-4 inhibitors at a later meeting date.

## VI. Retrospective DUR

### a. Old Business

#### i. Current Profile Review

##### 1. Stimulant use in adults

- a. Spencer Moore presented data on the utilization of stimulants in the adult Medicaid population. The Board made no further recommendations.

##### 2. Adherence to HIV and TB medications

- a. Stutzman informed the Board of the various medical and non-medical services provided by the Nebraska Department of Public Health that assist with medication adherence for patients with tuberculosis. Stutzman also presented information on the Ryan White DHHS Public Health program, which provides assistance for those living with HIV/AIDS.
- b. Spencer Moore presented DHHS public health and Medicaid data on medication adherence to HIV medications and data regarding patients enrolled in the Ryan White program. The Board made no further recommendations.

### b. New Business

#### i. Recommendations for Future Profile Review

##### 1. Substance use disorder treatment education

Stutzman discussed the recent increased trend of suspected opioid overdoses in Nebraska. Data was presented and Stutzman introduced a State developed guidance document aimed at helping providers understand buprenorphine. Several attendees made suggestions for additions to the guidance document. A motion was made to send out the guidance document to prescribers and pharmacies, as well as to measure utilization of buprenorphine now and 6 months from now.

Vote: Unanimous yes

## VII. Prospective DUR

### a. Old Business-Fee For Service PA review

#### i. Hereditary Angioedema

1. Dianne Garside presented the Hereditary Angioedema PA form. No comments from the Board.

#### ii. Hepatitis C drugs

1. Garside presented both the criteria and PA form for Hepatitis C. Garside noted previous changes regarding removal of sobriety restrictions. No comments from the Board. Amy Hornig presented testimony on behalf of AbbVie. Jodi Fuehrer, APRN, provided testimony as well.

### b. New Business

#### i. Zepbound-New Indication

1. Garside presented a draft policy regarding the new indication for Zepbound which was FDA approved for Obstructive Sleep Apnea. A motion was made for the DUR Board to approve the policy document with the recommended changes pending medical director review.

Vote: Unanimous yes

ii. New Drug Reviews

1. Tryngolza

Garside also presented draft criteria regarding the newly approved drug Tryngolza. A motion was made to approve the draft criteria.

Vote: Unanimous yes

VIII. Special Requests from the Department

a. None

IX. Future Meeting Dates

a. September 9<sup>th</sup>, 2025

b. October 28<sup>th</sup>, 2025

X. Concerns and Comments from the DUR Board

a. Charlie Moore comments on the appeals process with the MCOs.

b. Titchener made a motion to see Hepatitis C treatment medication fill data from the last calendar year, broken down by Nebraska PDL preferred vs non-preferred.

Vote: Unanimous yes

XI. Concerns and Comments from the DUR Director

a. None

XII. Concerns and Comments from the State DHHS Representatives

a. None

XIII. Concerns and Comments from the MCO Representatives

a. None

XIV. Concerns and Comments from the Public Attendees

a. None

XV. Adjournment

a. A motion was made to adjourn the meeting at 7:50pm.

Vote: Unanimous yes.